Patients with uremia due to urinary obstruction should be treated to relieve the obstruction, and the cause should be identified to establish a long-term treatment plan
SURMOUNT-1 (tirzepatide, 72 weeks): Discontinuation due to AEs: 4.3% (5 mg), 7.1% (10 mg), 6.2% (15 mg) vs 2.6% placebo Key characteristics: GI events occur primarily during dose escalation The GIP component does not appear to add substantial GI burden beyond GLP-1 effects Pooled SURMOUNT-1 to -4 analysis showed treatment discontinuation due to GI AEs ranged from 1.0% to 10.5% Retatrutide# Retatrutide adds glucagon receptor agonism to GLP-1 and GIP, creating a triple agonist
Mice were anaesthetized with a mixture of oxygen and isoflurane and placed in prone position inside the RF coil
doi: 10.1097/MCA.0000000000000830 120 GotoHNomiyamaTMitaTYasunariEAzumaKKomiyaKet al
People with naturally sensitive stomachs, a history of IBS, or a tendency toward loose stools may feel these effects more strongly
On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog